| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/19/2008 | WO2008072534A1 Solid medicinal preparation containing mannitol or lactose |
| 06/19/2008 | WO2008072533A1 Method for producing solid preparation |
| 06/19/2008 | WO2008072532A1 Pharmaceutical composition having improved storage stability |
| 06/19/2008 | WO2008072379A1 Method for producing modified biopolymer and method for crosslinking biopolymers |
| 06/19/2008 | WO2008072230A1 Novel injectable chitosan mixtures forming hydrogels |
| 06/19/2008 | WO2008072206A2 Composition comprising pyrithione or a polyvalent metal salt of a pyrithione and furametpyr |
| 06/19/2008 | WO2008072155A1 Active ingredient delivery system with an amorphous metal salt as carrier |
| 06/19/2008 | WO2008071966A2 Pharmaceutical composition of zolpidem |
| 06/19/2008 | WO2008071757A1 Particulate composition comprising calcium lactate and calcium citrate microparticles |
| 06/19/2008 | WO2008071594A2 Polypeptides with the capacity to entrap drugs |
| 06/19/2008 | WO2008071573A2 Powder formulation for valganciclovir |
| 06/19/2008 | WO2008071528A1 Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops |
| 06/19/2008 | WO2008071429A2 Oral contraceptive spray |
| 06/19/2008 | WO2008071407A2 Coated pellets |
| 06/19/2008 | WO2008071394A1 Abeta antibody parenteral formulation |
| 06/19/2008 | WO2008070996A1 Medical implants with a combination of compounds |
| 06/19/2008 | WO2008070982A1 Archaeal polar lipid aggregates for administration to animals |
| 06/19/2008 | WO2008070961A1 Linker-based lecithin microemulsion delivery vehicles |
| 06/19/2008 | WO2008070950A1 Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms |
| 06/19/2008 | WO2008051513A3 Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
| 06/19/2008 | WO2008051283A3 A dried biotherapeutic composition, uses, and device |
| 06/19/2008 | WO2008051245A3 Nanoparticles for use in immunogenic compositions |
| 06/19/2008 | WO2008049516A3 Transdermal therapeutic system comprising norelgestromin for contraception and hormone replacement |
| 06/19/2008 | WO2008049043A3 Ophthalmic compositions comprising diglycine |
| 06/19/2008 | WO2008049042A3 Ophthalmic compositions containing diglycine |
| 06/19/2008 | WO2008047320A3 Multiple unit tablet compositions of benzimidazole compounds |
| 06/19/2008 | WO2008046606A3 Topical composition for the treatment of eczema |
| 06/19/2008 | WO2008045806A3 Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions |
| 06/19/2008 | WO2008045563A3 Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
| 06/19/2008 | WO2008040665A3 Capecitabine pediatric tablets |
| 06/19/2008 | WO2008039351A3 Method of manufacturing tablets containing pharmacologically active agents |
| 06/19/2008 | WO2008039052A3 Process for stabilizing famotidine |
| 06/19/2008 | WO2008033300A8 Bis (thiohydrazide amides) formulation |
| 06/19/2008 | WO2008028264A8 Process for the production of micro-capsules having magnetic properties, product obtained therefrom and method for the controlled release of active substances |
| 06/19/2008 | WO2008023390A3 Modified release pharmaceutical composition of bupropion hydrochloride |
| 06/19/2008 | WO2008006534A3 Multiple unit tablets |
| 06/19/2008 | WO2008005705A3 Metal-containing formulations and methods of use |
| 06/19/2008 | WO2007147882A3 Aqueous suspensions of tmc278 |
| 06/19/2008 | WO2007147371B1 Pharmaceutical composition for oral administration |
| 06/19/2008 | WO2007137732A3 Autodestructive transdermal therapeutic system |
| 06/19/2008 | WO2007110709A8 Formulations of tipifarnib for intravenous administration |
| 06/19/2008 | WO2007099446A3 Virosome-like vesicles comprising gp41-derived antigens |
| 06/19/2008 | WO2007036646A8 Injectable viscous medicinal preparation comprising ethanol and an x-ray opaque fat-soluble compound |
| 06/19/2008 | WO2007019845A8 Method for encapsulating therapeutic substances in cells |
| 06/19/2008 | WO2007010032A3 Intermolecular association complex of a carrier, preferably an n-alkylamino -1-desoxylactitol and of an active ingredient |
| 06/19/2008 | US20080147050 External Infusion Device With Remote Programming, Bolus Estimator and/or Vibration Alarm Capabilities |
| 06/19/2008 | US20080147022 Skin care delivery device having a releasable backing |
| 06/19/2008 | US20080147004 External Infusion Device With Remote Programming, Bolus Estimator and/or Vibration Alarm Capabilities |
| 06/19/2008 | US20080146821 Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension |
| 06/19/2008 | US20080146671 Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amide renin inhibitor in absorption enhancing carrier comprising lipophilic component, high HLB surfactant, hydrophilic component, which on mixing forms stable microemulsion concentrate; bioavailability; side effect reduction; cardiovascular disorders |
| 06/19/2008 | US20080146668 Method for stimulating weight loss and/or for lowering triglycerides in patients |
| 06/19/2008 | US20080146652 Anhydrous formulations formed of diblock copolymer having hydrophilic block and hydrophobic block, an additive selected from a polymer and an organic solvent, the solvent being water-miscible and biocompatible, and a drug; provides for formation of micelles having enhanced ability to incorporate drugs |
| 06/19/2008 | US20080146651 Injectable Composition for the Treatment of Cancers |
| 06/19/2008 | US20080146581 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety |
| 06/19/2008 | US20080146530 Re-epithelializing pharmaceutical compositions comprising xanthan gum |
| 06/19/2008 | US20080146529 Skin peeling composition and method |
| 06/19/2008 | US20080146472 Viscous liquid with mucosa moistening; for delivering medication, skin moisturizing and to enhances sexual experiences; comprising linseed and a seed polysaccharide extract soluble in water, a pH buffer (citric acid), and preservative for prevention of growth of micro-organisms and stability |
| 06/19/2008 | US20080146109 Laminates of acid polysaccharide films |
| 06/19/2008 | US20080145456 Aethereum gerani, Aethereum rosmarini, Aethereum citri, Mentholum, and ethylene-diamine-tetra-acetic acid-alkali metal salt (EDTA); eliminating pain of different locomotor complaints of the body |
| 06/19/2008 | US20080145441 Core of metal atoms of gold, silver or copper covalently linked to a carbohydrate group and to at least 20 ligands |
| 06/19/2008 | US20080145440 Cisplatin intercalated into the double-helical DNA; stably retains cisplatin and exhibits an excellent slow-release property |
| 06/19/2008 | US20080145439 Nanoparticle drug formulations |
| 06/19/2008 | US20080145438 Melting a drug in a molten miscible surfactant; heating the mixture; and cooling the mixture while continuously mixing under high; maximizing precipitation of drug particles coated with the surfactant and having a greater rate of dissolution than pure unprocessed drug |
| 06/19/2008 | US20080145437 First and a second microencapsulated composition, wherein the first composition comprises an oxidizing agent and the second comprises a reducing agent; upon rupture, a reaction occurs between the oxidizing agent and the reducing agent |
| 06/19/2008 | US20080145436 Aqueous phase dispersed in an oily phase, a silicone emulsifier, a hydrophilic acrylic polymers and 2-acrylamido-2-methylpropanesulfonic acid polymers, and a silicon-based filler |
| 06/19/2008 | US20080145435 Composition Comprising a Volatile Solvent, an Organic Filler and a Mineral Filler, and Uses Thereof |
| 06/19/2008 | US20080145434 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
| 06/19/2008 | US20080145433 Darusentan oral dosage form |
| 06/19/2008 | US20080145431 High-pressure homogenization of a process liquid containing a drug in an amount which exceeds a saturation level while controlling a temperature of the process liquid so as to exceed a solidifying point of the process liquid and be lower than a boiling point |
| 06/19/2008 | US20080145430 With a surface stabilizer adsorbed on the surface; non-irritating and sufficiently bioavailable |
| 06/19/2008 | US20080145429 Dosage Form Containing Oxycodone and Naloxone |
| 06/19/2008 | US20080145428 Mascara Composition Containing Shape-Memory Polymers, Gels, and Fibers |
| 06/19/2008 | US20080145427 Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors |
| 06/19/2008 | US20080145426 Personal care products for the skin comprising an encapsulation layer surrounding an aqueous core composition of an encapsulating activator, a matrix, and an active agent where the microencapsule has a diameter of 5-5000 micrometers; stability; moisturizers, conditioners, cleaning compounds, wipes |
| 06/19/2008 | US20080145425 Pharmaceutical composition of zolpidem |
| 06/19/2008 | US20080145424 Also including 0.5-5 % polyvinylpyrrolidone and 5-40 % hydroxypropyl methylcellulose; administering an endothelial nitric oxide synthase agonist (an HMG-CoA reductase inhibitor) and a NO precursor (L-arginine hydrochloride) for cerebrovascular/cardiovascular disorders; anticholesterol agents |
| 06/19/2008 | US20080145423 Chewable tablet and method of formulating |
| 06/19/2008 | US20080145422 Galantamin, particularly galantaminehydrobromide, and carrier of a blend of lactose-based diluent and microcrystalline cellulose; excellent content uniformity and dissolution properties; adjuvants such as disintegrants, glidants, lubricants, and coating agents; direct compression; hardness of 20-40 kP |
| 06/19/2008 | US20080145421 Stabilized composition |
| 06/19/2008 | US20080145420 Multimeric immunoglobulin for use in prevention and treatment of viral and microorganismal infection |
| 06/19/2008 | US20080145419 High viscosity liquid controlled delivery system and medical or surgical device |
| 06/19/2008 | US20080145418 Diindolylmethane for the treatment of HPV infection |
| 06/19/2008 | US20080145417 Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof |
| 06/19/2008 | US20080145416 Cross-linked ionic core micelles |
| 06/19/2008 | US20080145415 Bioresorbable Fillers Constituted by Phospholipid Liposomes and Hyaluronic Acid and/or the Derivatives Thereof |
| 06/19/2008 | US20080145414 Method of Producing Fine Particles Surface-Modified with Water-Soluble Substance |
| 06/19/2008 | US20080145413 Lipids and lipid assemblies comprising transfection enhancer elements |
| 06/19/2008 | US20080145412 Administering a carrier and a 10-30 amino acids-containing peptide which has an integrin binding motif and a glycosaminoglycan binding motif; contact with cells to stimulate by induction of fibroblast and transforming growth factors (FGF2, TGF beta) and fibronectin; high potency; well-tolerated; bandages |
| 06/19/2008 | US20080145411 Oxidized coenzyme Q10, a lysolecithin and an oil and fat where the weight ratio of the lysolecithin to the Q10 is >0.7: superior absorption; bioavailabiliry; stability; heat resistance; photostabiliy; food supplement; nutrients drugs; beverages; feet; pet food, cosmetics; nutraceuticals; soft capsules |
| 06/19/2008 | US20080145410 An iron-containing complex to treat hyperphosphatemia by adsorbing excess phosphates in the blood; capacity of >140 mg adsorbed phosphate by 1 g complex of an insoluble carbohydrate (starch), polynuclear iron oxide/hydroxide and a soluble glucose; stability; packaging; industrial scale |
| 06/19/2008 | US20080145408 Soluble salts of Group Ia and 2a metal hydroxides; appetite suppression; weight loss; increase in fat metabolism rate; reduction in blood lipids and postprandial lipemia; increase the plasma level of (-)-hydroxycitric acid; bioavailability; dietetics; extracted from dried Garcinia rind |
| 06/19/2008 | US20080145404 Methods and compositions for regenerating connective tissue |
| 06/19/2008 | US20080145403 Heating a mixture of cyclic lipid (bimatoprost) and a biodegradable polymer (polylactic acid) to 50-80 degrees C. and extruding; sustained release of the drug at >50 % of its potency;side effect reduction; amorphous drug forms; by-products inhibition; administering implants subconjunctivally |
| 06/19/2008 | US20080145402 Polymer coatings as carriers for the drug delivery of an hydroxyethylated ether derivative of rapamycin (A-179578) and another drug(s) such as an antiproliferative agent, anticoagulant, etc.; reduces restenosis in vasculature procedures to a level of 0-25%; coronary/periferal stents; grafts ; balloons |
| 06/19/2008 | US20080145401 use in sclerotherapy of blood vessels; injecting blood dispersible gases carbon dioxide and/or oxygen, and a sclerosing agent polidocanol; avoiding use of potentially hazardous amounts of nitrogen; treating varicose veins disorders; drug delivery method |
| 06/19/2008 | US20080145388 Product for the Targeted Release of Two-Compartment Active Substances |
| 06/19/2008 | US20080145387 N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(-9-tetradeceneyloxy)-1 -propanaminium salt; cytofectin and lipid mixture |
| 06/19/2008 | US20080145319 Compositions containing Anthocyanosides and/or Procyanidins, Isoquinoline alkaloids extracted from Sanguinaria canadensis, Macleaya cordata or Macleaya microcarpa, and optionally a Zanthoxylum bungeanum and/or Echinacea angustifolia lipophilic extract; for treatment of throat redness and inflammation |
| 06/19/2008 | US20080145318 Atomoxetine agent may be any atomoxetine prodrug or metabolite that has been modified to alter rate at which drug is metabolized; such a modification may be accomplished, inter alia, by blocking phenoxy 4 position of atomoxetine agent; attention-deficit/hyperactivity disorders, asthma, allergies |
| 06/19/2008 | US20080145317 Comprising 10 to 65 wt % florfenicol, 20 to 80 wt % of an alkaline component, and 0 to 60 wt % of an acid component; capable of effervescence in presence of moisture; rapidly solubilizing additive for addition to drinking water systems for treatment of bacterial infections in animals |